When was DalCor founded?

DalCor was founded in 2015 and raised its 1st funding round within a year of its incorporation.

Where is DalCor located?

DalCor is headquartered in Montreal, Canada. It is registered at 2001 Robert-Bourassa Blvd, Montréal.

Which legal entities is DalCor associated with?

DalCor is associated with DalCor Pharmaceuticals Canada Inc. and 1 other.

Is DalCor a funded company?

DalCor is a funded company, having raised a total of $234M across 5 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on 2015.

When was the latest funding round of DalCor?

DalCor's latest funding was a $***** Series D round on Sep 13, 2023, with participation from 3 investors. Its primary sector is Cardiac and Vascular Disorders. Globally, the Cardiac and Vascular Disorders sector has seen $1.45B in funding in 2026 to date.

Where does DalCor rank among its competitors?

DalCor ranks 7th amongst 17 active competitors, of which 5 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was XyloCor Therapeutics, which secured $67.5M in Jan, 2025.

Who are the top competitors of DalCor?

DalCor's top competitors include Verve, XyloCor Therapeutics and Lisata. Among them, XyloCor Therapeutics secured the most recent funding round in January, 2025.

DalCor - 2026 Company Profile, Team, Funding & Competitors

DalCor is a series D company based in Montreal (Canada), founded in 2015. It operates as a Developer of small molecules therapeutics for cardiovascular diseases. DalCor has raised $234M in funding from Sanderling Ventures and Invest Quebec. The company has 17 active competitors, including 5 funded and 4 that have exited. Its top competitors include companies like Verve, XyloCor Therapeutics and Lisata.

Company Details

DalCor Pharmaceuticals develops small molecule therapeutics for cardiovascular diseases. Its lead candidate Dalcetrapib is a cholesterol ester transfer protein (CETP) inhibitor to treat the cardiovascular disease risk caused by the mutations in the ADCY9 gene. Dalcetrapib is currently in phase III trials for the treatment of a genetic subpopulation of patients suffering from Acute Coronary Syndrome (ACS).

Website: dalcorpharma.com
Registered Address: 2001 Robert-Bourassa Blvd, Montréal

Key Metrics

Founded Year

2015

Location

Montreal, Canada

Stage

Series D

Total Funding

$234M in 5 rounds

Latest Funding Round

Series D, Sep 13, 2023, $*****

Investors

Sanderling Ventures & 5 more

Ranked

7^th among 17 active competitors

Similar Companies

Verve & 21 more

View DalCor's full profile

DalCor is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Dalcor CIN: 40103818046 , Latvia, Deadpooled	Aug 18, 2014	€0 - €1M (As on Dec 31, 2020)	1 (As on Dec 31, 2020)	-
DalCor Pharmaceuticals Canada Inc. CIN: 915856-1 , Canada, Active	Jan 19, 2015	-	-	-

DalCor has raised a total funding of $234M over 5 rounds. Its first funding round was on 2015. Its latest funding round was a Series D round on Sep 13, 2023 for $*****. 3 investors participated in its latest round. DalCor has 5 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of DalCor:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 13, 2023	9948225	Series D	6789237	4979713	9688042	6255872
May 12, 2020	4039750	Series B	5633979	6007585	8531400	8646973
May 12, 2020	9953535	Conventional Debt	4759580	8366480	2451773	8004028

Access funding benchmarks and valuations. Sign up today!

View details of DalCor's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of DalCor include Verve, XyloCor Therapeutics and Lisata. Here is the list of Top 10 competitors of DalCor, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Verve 2018, Cambridge (United States), Acquired	Developer of gene-editing therapies for treating coronary artery disease	$216M	Google Ventures, Casdin Capital & 14 others	66/100
2nd	XyloCor Therapeutics 2013, Newtown Square (United States), Series B	Developer of gene therapies for the treatment of coronary arterial disease	$111M	Life Sciences Partners, Sofinnova Investments ... & 5 others	60/100
3rd	Lisata 2006, Basking Ridge (United States), Acquired	Developer of therapeutics for cancer and vascular disorders	$6.58M	Kyoto University Innovation Capital, HHS & 1 others	57/100
4th	Bitterroot Bio 2021, Palo Alto (United States), Series A	Immunotherapy to develop and deliver medicines for cardiovascular disease	$145M	Deerfield, Arch Venture Partners & 3 others	57/100
5th	Cadrenal Therapeutics 2022, Ponte Vedra Beach (United States), Public	Developer of therapeutics for renal disease and atrial fibrillation	$400K	-	55/100
6th	Elevian 2017, Boston (United States), Series A	Developer of regenerative therapies for treating age-related diseases	$60.8M	Prime Movers Lab, Western Technology Investment ... & 11 others	48/100
7th	DalCor 2015, Montreal (Canada), Series D	Developer of small molecules therapeutics for cardiovascular diseases	$234M	CTI Life Sciences Fund, Invest Quebec & 4 others	42/100
8th	Cyclarity Therapeutics 2019, Novato (United States), Series A	Developer of therapeutics for cardiovascular diseases	$21.7M	Starbloom Primrose, Kizoo & 3 others	39/100
9th	Gene Biotherapeutics 2003, San Diego (United States), Public	Developer of gene therapeutics for cardiovascular diseases	$750K	-	32/100
10th	Ayma Therapeutics 2019, Ann Arbor (United States), Unfunded	Provider of cardiovascular therapies for Atherosclerotic cardiovascular disease (ASCVD) patients	-	-	30/100